Key points are not available for this paper at this time.
Chimeric antigen receptor (CAR) T cells and bispeci fi c antibodies are mainly used to treat hematologic malignancies, 1 including multiple myeloma (MM). MM is the second most common hematologic malignancy and remains a largely incurable disease. 2,3 It is characterized by the proliferation of clonal plasma cells in the bone marrow 2,3 and high expression of CD38 and B-cell maturation antigen (BCMA). 4 Patients who are refractory to a proteasome inhibitor, immunomodulatory agents, and monoclonal antibodies have a poor prognosis. Therefore, new treatment strategies are necessary. 5 Targeting BCMA, present on malignant and normal plasma cells, either by CAR T cells or by anti-BCMA bispeci fi c antibodies, has become the gold standard to treat refractory MM. 5 Persistence and expansion of CAR T cells is associated with superior outcomes. 6 Therefore, the detection of CAR T cells in the blood is an essential parameter to make clinical decisions
Glatte et al. (Fri,) studied this question.